No abstract

case reports/case series 521 CAN J ANESTH 55: 8 www.cja-jca.org August, 2008 Purpose: To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid). Serotonin toxicity precipitated by fentanyl is unusual and has not previously been described in combination with SSRIs in the perioperative setting. Clinical features:A 60-yr-old woman, established on paroxetine for depression, underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction. Fentanyl was administered for intraoperative and postoperative analgesia (1 mg intraoperatively, and 2.5 mg by infusion in the first 36 hr, postoperatively). She developed a vague affectation, intermittent agitation, bilateral hyper-reflexia, inducible clonus, and a period of hypertension, suggestive of serotonin toxicity. There was complete resolution after cessation of fentanyl and paroxetine. Conclusion:The co-administration of SSRIs and fentanyl may precipitate serotonin toxicity. There must be consideration of this unusual interaction when administering fentanyl to patients established on SSRIs. Physicians should be vigilant of the features of serotonin toxicity developing in such patients. SEroToNiN (5-hydroxytryptamine, 5-HT) is a neurotransmitter concentrated in the raphe nuclei of the brainstem reticular formation of the central nervous system (CNS). it is involved in regulating the sleep-wakefulness cycle, mood, appetite, emotion, temperature, and the motor system. 1 The serotonin syndrome, or serotonin toxicity, is a well-documented series of clinical features resulting from drug-induced serotonergic hyperstimulation in the CNS.

A 72-year-old woman was admitted for a routine elective total knee replacement. By day 1 postoperative, she became hyponatraemic following an Addisonian crisis, leading to an admission into the intensive therapy unit (ITU). It was later during this stay in the ITU and on a retrospective drug history review that she was found to have taken clobetasol, a high strength topical steroid cream over the past 2 years. The authors alert the reader to the importance of specially asking patients about their use of current or recent topical steroid creams as they may not always volunteer this information. Sudden withdrawal of steroid supplementation in these patients in the preoperative period may result in catastrophic consequences.

No abstract

No abstract